A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Sponsor: MoonLake Immunotherapeutics AG
Listed as NCT07223138, this observational or N/A phase trial focuses on Arthritis, Psoriatic and remains ongoing. Sponsored by MoonLake Immunotherapeutics AG, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)M1095-PSA-303 is a Phase 3, multicenter, open-label extension study to investigate the long-term safety, tolerability and clinical efficacy of sonelokimab 60 mg subcutaneously every 4 weeks in patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302).
M1095-PSA-303 is a Phase 3, multicenter, open-label extension study to investigate the long-term safety, tolerability and clinical efficacy of sonelokimab 60 mg subcutaneously every 4 weeks in patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302).
Status Flow
Change History
4 versions recorded-
Apr 28, 2026 — Present [daily]
Enrolling By Invitation
Phase: PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Nov 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
Contact Information
- MoonLake Immunotherapeutics AG
For direct contact, visit the study record on ClinicalTrials.gov .